Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Dexcom

- PMLiVE

Novo Nordisk’s Tresiba gaining ground in basal insulin market

Delivers $216m this year despite ICER's report of insufficient data to favour the drug over Sanofi's Lantus

- PMLiVE

EU clears AZ’s FDA-rejected diabetes combination

Approval of two-drug therapy Qtern presents first-to-market advantage in Europe

- PMLiVE

Diabetes treatment ‘inextricably’ linked to patient education

Condition remains a significant burden for health systems

Google takes aim at blindness with NHS research deal

DeepMind Health partners with Moorfields Eye Hospital NHS Foundation Trust

- PMLiVE

Novo’s world-leading insulin plant to get even bigger

Danish firm invests €54m in Kalundborg expansion

- PMLiVE

Ypsomed’s touch screen insulin pump for Novo Nordisk approved by EMA

mylife YpsoPump given green light for use with pump cartridge NovoRapid PumpCart

- PMLiVE

Diabetes UK uses Lego to address diabetes myths

Teams up with Brickabetes to document the highs and lows of living with diabetes

Sanofi reception

Sanofi launches community health project in China

Partners with local associations to improve chronic disease management

- PMLiVE

Updated EMPA-REG data show Jardiance also protects kidney

Boehringer Ingelheim and Lilly’s drug is the first to show positive impact on kidney damage

- PMLiVE

Victoza cuts cardiovascular risk in landmark study

Novo Nordisk’s diabetes therapy outcomes ‘beyond expectations’

- PMLiVE

Novo creates online diabetes management resource

Aims to educate UK patients and the public on the signs and impact of hypos

Sanofi reception

Sanofi boosted by iGlarLixi trials at ADA

Combination of Lantus and Lyxumia showed greater efficacy in controlling type 2 diabetes

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links